Detection method of H7N9 avian influenza

Nucleic acid detection (NAT) is a general term for a series of technologies to directly detect pathogen nucleic acids, which can detect virus nucleic acids before detecting antigens or antibodies. Its basic steps include nucleic acid extraction, amplification and detection. In other words, genetic testing is a technology to detect DNA through blood, other body fluids or cells, which can diagnose diseases and predict disease risks. Because nucleic acid detection is a direct detection of pathogen nucleic acid, it has the advantages of high sensitivity, strong specificity and short detection window, which has won time for early diagnosis, early treatment, reducing mortality and controlling epidemic situation. Nucleic acid detection technology has developed from qualitative detection to real-time fluorescence quantitative detection. In view of some clinical needs, besides confirming cases according to yin and yang, we can also judge the degree of infection according to the load of nucleic acid. Detection equipment According to national standards, the detection of H7N9 avian influenza virus nucleic acid requires real-time fluorescence quantitative PCR instrument for quantitative detection or PCR gene amplification instrument for qualitative detection. According to the specific sequence of human infected H7N9 avian influenza virus nucleic acid, a PCR detection kit based on primers and probes is developed.

On April 2, 20 13, the National Center for Disease Control and Prevention has started the logistics procedure, and distributed the nucleic acid detection PCR reagent probes and primers for detecting H7N9 avian influenza virus to local CDC and diagnostic laboratories to ensure the accurate diagnosis of H7N9.

20 13 In late April, the RNA detection kit for influenza A (H7N9) virus developed in Beijing has passed the evaluation of national experts in emergency medical device approval, becoming the first batch of products in Chinese mainland to enter the "green channel" for rapid approval. Clinical trials show that the kit can screen whether people are infected with H7N9 virus within two and a half hours, which will effectively guarantee the prevention and control of influenza A (H7N9) virus.